Figure 5

Consistent expression indices derived from stage III ovarian cancer are associated with treatment response. Ovarian cancer-derived CEI2 predicted pathological complete response (pCR) to paclitaxel monotherapy and non-pCR to carboplatin monotherapy in CRUK ovarian cancer cohort.